Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654639 · ClinicalTrials.gov registry record · Phase 2
Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02654639: Clinical Trial Phase 2 study, sponsored by Georgetown University.
NCT02654639 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02654639, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
Primary Outcome
Disease progression will be assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI.
Interventions
- DRUG Bevacizumab
- DRUG TAS-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Why NCT02654639 stopped before completion
NCT02654639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02654639 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02654639 about?
NCT02654639 is a clinical study titled "Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer". Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
What is the current status of trial NCT02654639?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2016-02. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02654639?
The interventions under investigation include: Bevacizumab (DRUG), TAS-102 (DRUG).
Who is sponsoring clinical trial NCT02654639?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02654639's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia